Although murine models have been used to study the effects of less commonly used salvage therapies, such as rituximab and low-dose IL-2 administration, data on the effects of CNI or mTOR-I in murine AIH models are unfortunately lacking to date. The gene discussed is IL2; the disease is autoimmune hepatitis.